Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eszopiclone and CPAP in Obstructive Sleep Apnea
NCT07332442Phase 3Recruiting
- Sponsor
- Yale University
- Start
- May 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Eszopiclone with Placebo (2 arms). Primary endpoints: Continuous Positive Airway Pressure adherence at 3 months and Flanker inhibitory control and attention test at 3 months. Started May 2026; status: recruiting.
02
Drugs
eszopiclone
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT07332442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332442.